Issue 4 BioHire RoundUp
Will the Trump Administration Create More Headwinds for the Biopharma Sector? What’s in store? Donald Trump’s return to the presidency has the potential to bring significant changes to U.S. health care policy. His administration promised to empower figures like...
Issue 3 BioHire RoundUp
Glassdoor’s Decline: Why Going Back to Basics is (and has always been) Key for Genuine Company Insights Glassdoor was once the go-to for semi-authentic company reviews, but since its acquisition by Recruit Holdings Co., Ltd., it seems the site is being...
Issue 2 BioHire RoundUp
Dive into the latest biotech Buzz! Discover groundbreaking advancements, regulatory updates, and insights shaping the biotech landscape. The Defeat of Non Compete? The Federal Trade Commission (FTC) has implemented a rule banning most noncompete agreements, aiming to...
BioHire RoundUp
Dive into the latest biotech Buzz! Discover groundbreaking advancements, regulatory updates, and insights shaping the biotech landscape. Links to some of the most interesting news from across the internet, curated by our team: Renewed hope as biotech heads into 2024...Journal Articles
-
-
Good Scientist, Bad Interviewer?
Structured interviews and setting aside first impressions can help biotech hiring managers uncover talented but reserved candidates, ensuring strong scientists aren't overlooked due to interview style or first impressions. Shifting focus to “screening in” candidates promotes a more accurate assessment of both technical and soft skills.
Categories: Issue 4: Q4 2024
-
Backdoor References in Recruitment: Insight or Invasion?
Backdoor references can offer valuable insights into a candidate's skills and work ethic beyond their formal references, but hiring managers must handle them with care to ensure credibility and confidentiality. These informal checks should complement structured interviews rather than serve as the primary assessment tool.
Categories: Issue 4: Q4 2024
-
Biotech: Where Failure is Likely, Money Is Fleeting, and Layoffs are Inevitable
Clinical drug development is costly and has a failure rate over 90%, necessitating significant external funding for small companies. As mergers and acquisitions increase amid fierce competition and patent expirations, ongoing layoffs create opportunities for organizations to acquire talent.
Categories: Issue 4: Q4 2024
-
In Person-Interviewing: A Relic of the Past?
Biotech talent acquisition has increasingly embraced virtual interviews, yet many professionals stress the importance of in-person assessments for cultural fit. A blended approach of virtual and face-to-face interviews, along with behavioral evaluations, is crucial for identifying the best candidates.
Categories: Issue 4: Q4 2024
